<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02426632</url>
  </required_header>
  <id_info>
    <org_study_id>CR106726</org_study_id>
    <secondary_id>53718678RSV1003</secondary_id>
    <secondary_id>2014-005157-39</secondary_id>
    <nct_id>NCT02426632</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Taste Profile of Different JNJ-53718678 Oral Liquid Formulations in Healthy Participants</brief_title>
  <official_title>A Phase 1, Double-blind, Randomized, Trial to Evaluate the Taste Profile of Different JNJ-53718678 Oral Liquid Formulations in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Sciences Ireland UC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Sciences Ireland UC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate in a double-blinded (neither physician nor participant&#xD;
      knows the treatment that the participant receives), fashion the taste of different&#xD;
      JNJ-53718678 oral liquid formulations as compared to the reference formulation (JNJ-53718678,&#xD;
      10 milligram/milliliter oral solution without sweetener/flavor).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, double-blind, randomized (participants taste the same groups of drugs&#xD;
      [formulations] but in random order), single-center trial in healthy adult participants. The&#xD;
      study will include 2 Sessions of 1 day, 1) Session 1, in which participants will receive 6&#xD;
      JNJ-53718678 oral solutions (1 reference and 5 different formulations) sequentially in a&#xD;
      randomized order, Scoring of the taste will be done via a questionnaire designed for this&#xD;
      purpose; 2) Session 2, within approximately a timeframe of 7 to 14 days after completion of&#xD;
      Session 1, participants will taste 2 best scoring tastes coming out of Session 1. The study&#xD;
      will consist of a screening phase of approximately 2 weeks, treatment phase of approximately&#xD;
      2 weeks and a post-treatment follow-up phase of 10 days after completion of the last Session.&#xD;
      The total study duration for each participant will be approximately 6 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 4, 2015</start_date>
  <completion_date type="Actual">April 24, 2015</completion_date>
  <primary_completion_date type="Actual">April 24, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acceptability Score</measure>
    <time_frame>up to 12 hour post-administration of study drug</time_frame>
    <description>Formulations will be assessed using Acceptability Questionnaire, which evaluates sweetness, bitterness, aroma type, aroma strength, smell and overall acceptability using visual analogue scales (VAS) with range from 0 (super bad) to 100 (super good).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Local and Systemic adverse Events</measure>
    <time_frame>Screening up to end of Study (Week 6)</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Session 1: Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 1: Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 1: Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 1: Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 1: Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 1: Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 2: Sequence 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 2: Sequence 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 2: Sequence 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 2: Sequence 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 2: Sequence 11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 2: Sequence 12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation A</intervention_name>
    <description>Reference formulation, 10 milligram/milliliter (mg/mL)oral solution without sweetener/flavor.</description>
    <arm_group_label>Session 1: Sequence 1</arm_group_label>
    <arm_group_label>Session 1: Sequence 2</arm_group_label>
    <arm_group_label>Session 1: Sequence 3</arm_group_label>
    <arm_group_label>Session 1: Sequence 4</arm_group_label>
    <arm_group_label>Session 1: Sequence 5</arm_group_label>
    <arm_group_label>Session 1: Sequence 6</arm_group_label>
    <other_name>JNJ-53718678</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation B</intervention_name>
    <description>10 mg/mL oral solution containing 2 mg/mL sucralose, masking flavor and orange flavor.</description>
    <arm_group_label>Session 1: Sequence 1</arm_group_label>
    <arm_group_label>Session 1: Sequence 2</arm_group_label>
    <arm_group_label>Session 1: Sequence 3</arm_group_label>
    <arm_group_label>Session 1: Sequence 4</arm_group_label>
    <arm_group_label>Session 1: Sequence 5</arm_group_label>
    <arm_group_label>Session 1: Sequence 6</arm_group_label>
    <other_name>JNJ-53718678</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation C</intervention_name>
    <description>10 mg/mL oral solution containing 10 mg/mL sucralose.</description>
    <arm_group_label>Session 1: Sequence 1</arm_group_label>
    <arm_group_label>Session 1: Sequence 2</arm_group_label>
    <arm_group_label>Session 1: Sequence 3</arm_group_label>
    <arm_group_label>Session 1: Sequence 4</arm_group_label>
    <arm_group_label>Session 1: Sequence 5</arm_group_label>
    <arm_group_label>Session 1: Sequence 6</arm_group_label>
    <other_name>JNJ-53718678</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation D</intervention_name>
    <description>10 mg/mL oral solution containing 2 mg/mL sucralose and raspberry flavor.</description>
    <arm_group_label>Session 1: Sequence 1</arm_group_label>
    <arm_group_label>Session 1: Sequence 2</arm_group_label>
    <arm_group_label>Session 1: Sequence 3</arm_group_label>
    <arm_group_label>Session 1: Sequence 4</arm_group_label>
    <arm_group_label>Session 1: Sequence 5</arm_group_label>
    <arm_group_label>Session 1: Sequence 6</arm_group_label>
    <other_name>JNJ-53718678</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation E</intervention_name>
    <description>10 mg/mL oral solution containing 2 mg/mL sucralose and strawberry flavor.</description>
    <arm_group_label>Session 1: Sequence 1</arm_group_label>
    <arm_group_label>Session 1: Sequence 2</arm_group_label>
    <arm_group_label>Session 1: Sequence 3</arm_group_label>
    <arm_group_label>Session 1: Sequence 4</arm_group_label>
    <arm_group_label>Session 1: Sequence 5</arm_group_label>
    <arm_group_label>Session 1: Sequence 6</arm_group_label>
    <other_name>JNJ-53718678</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation F</intervention_name>
    <description>10 mg/mL oral solution containing 2 mg/mL sucralose and orange flavor.</description>
    <arm_group_label>Session 1: Sequence 1</arm_group_label>
    <arm_group_label>Session 1: Sequence 2</arm_group_label>
    <arm_group_label>Session 1: Sequence 3</arm_group_label>
    <arm_group_label>Session 1: Sequence 4</arm_group_label>
    <arm_group_label>Session 1: Sequence 5</arm_group_label>
    <arm_group_label>Session 1: Sequence 6</arm_group_label>
    <other_name>JNJ-53718678</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation M1</intervention_name>
    <description>Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).</description>
    <arm_group_label>Session 2: Sequence 10</arm_group_label>
    <arm_group_label>Session 2: Sequence 11</arm_group_label>
    <arm_group_label>Session 2: Sequence 12</arm_group_label>
    <arm_group_label>Session 2: Sequence 7</arm_group_label>
    <arm_group_label>Session 2: Sequence 8</arm_group_label>
    <arm_group_label>Session 2: Sequence 9</arm_group_label>
    <other_name>JNJ-53718678</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation M2</intervention_name>
    <description>Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).</description>
    <arm_group_label>Session 2: Sequence 10</arm_group_label>
    <arm_group_label>Session 2: Sequence 11</arm_group_label>
    <arm_group_label>Session 2: Sequence 12</arm_group_label>
    <arm_group_label>Session 2: Sequence 7</arm_group_label>
    <arm_group_label>Session 2: Sequence 8</arm_group_label>
    <arm_group_label>Session 2: Sequence 9</arm_group_label>
    <other_name>JNJ-53718678</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation M3</intervention_name>
    <description>Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).</description>
    <arm_group_label>Session 2: Sequence 10</arm_group_label>
    <arm_group_label>Session 2: Sequence 11</arm_group_label>
    <arm_group_label>Session 2: Sequence 12</arm_group_label>
    <arm_group_label>Session 2: Sequence 7</arm_group_label>
    <arm_group_label>Session 2: Sequence 8</arm_group_label>
    <arm_group_label>Session 2: Sequence 9</arm_group_label>
    <other_name>JNJ-53718678</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation N1</intervention_name>
    <description>Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).</description>
    <arm_group_label>Session 2: Sequence 10</arm_group_label>
    <arm_group_label>Session 2: Sequence 11</arm_group_label>
    <arm_group_label>Session 2: Sequence 12</arm_group_label>
    <arm_group_label>Session 2: Sequence 7</arm_group_label>
    <arm_group_label>Session 2: Sequence 8</arm_group_label>
    <arm_group_label>Session 2: Sequence 9</arm_group_label>
    <other_name>JNJ-53718678</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation N2</intervention_name>
    <description>Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).</description>
    <arm_group_label>Session 2: Sequence 10</arm_group_label>
    <arm_group_label>Session 2: Sequence 11</arm_group_label>
    <arm_group_label>Session 2: Sequence 12</arm_group_label>
    <arm_group_label>Session 2: Sequence 7</arm_group_label>
    <arm_group_label>Session 2: Sequence 8</arm_group_label>
    <arm_group_label>Session 2: Sequence 9</arm_group_label>
    <other_name>JNJ-53718678</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation N3</intervention_name>
    <description>Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).</description>
    <arm_group_label>Session 2: Sequence 10</arm_group_label>
    <arm_group_label>Session 2: Sequence 11</arm_group_label>
    <arm_group_label>Session 2: Sequence 12</arm_group_label>
    <arm_group_label>Session 2: Sequence 7</arm_group_label>
    <arm_group_label>Session 2: Sequence 8</arm_group_label>
    <arm_group_label>Session 2: Sequence 9</arm_group_label>
    <other_name>JNJ-53718678</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female participants of childbearing potential should have a urine pregnancy test at&#xD;
             screening which should be negative&#xD;
&#xD;
          -  Participants must be non-smokers and/or have not used chewing tobacco for at least one&#xD;
             month prior to screening&#xD;
&#xD;
          -  Participants must be willing/able to adhere to the prohibitions and restrictions&#xD;
             specified in the protocol and study procedures&#xD;
&#xD;
          -  Participants must be able to taste and smell normally, to their own opinion, at all&#xD;
             times throughout the study duration. Participants who have an impaired sense of taste&#xD;
             and/or smell due to any conditions like common cold or sinusitis are not eligible to&#xD;
             take part or to continue to study&#xD;
&#xD;
          -  Participants must agree to use an adequate method of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has a mouth pathology including, but not limited to, pain, ulcer, edema,&#xD;
             mucosal erosion, and/or (dental) abscesses, or receives treatment for oral pathologies&#xD;
             or oral treatment for any disease&#xD;
&#xD;
          -  Participant has a history of any illness that, in the opinion of the Investigator,&#xD;
             might confound the results of the study or pose an additional risk in administering&#xD;
             study drug to the participant or that could prevent, limit or confound the protocol&#xD;
             specified assessments. This may include but is not limited to renal dysfunction,&#xD;
             significant cardiac, vascular, pulmonary, gastrointestinal (such as significant&#xD;
             diarrhea, gastric stasis, or constipation that in the Investigator's opinion could&#xD;
             influence drug absorption or bioavailability), endocrine, neurologic, hematologic,&#xD;
             rheumatologic, psychiatric, neoplastic, or metabolic disturbances&#xD;
&#xD;
          -  Participants with a history of clinically significant allergies, hypersensitivity, or&#xD;
             intolerance to drugs such as, but not limited to, sulfonamides and penicillins, drug&#xD;
             allergy witnessed in previous studies with experimental drugs, or to JNJ-53718678 or&#xD;
             its excipients&#xD;
&#xD;
          -  Participants with a history or evidence of use of alcohol, barbiturates, amphetamines,&#xD;
             recreational or narcotic drug use within the past 3 months, which in the&#xD;
             Investigator's opinion would compromise participant's safety and/or compliance with&#xD;
             the study procedures&#xD;
&#xD;
          -  Participants having received an investigational drug (including investigational&#xD;
             vaccines) or used an invasive investigational device within 3 months before the&#xD;
             planned first dose of study drugs or is currently enrolled in an investigational study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Sciences Ireland UC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Sciences Ireland UC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>April 22, 2015</study_first_submitted>
  <study_first_submitted_qc>April 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2015</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>JNJ-53718678</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

